Application of mesenchymal stem cells acting on immune barrier reconstruction of inflammation part
By using mesenchymal stem cells to regulate the inflammatory response, inhibit the secretion of inflammatory factors and promote the proliferation of anti-inflammatory cells, the problem of difficulty in effectively regulating the inflammatory response in the existing technology is solved, and the effects of reducing tissue inflammatory damage and promoting wound healing are achieved.
Patent Information
- Application Number
- CN202310897988.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-07-21
- Publication Date
- 2025-01-21
AI Technical Summary
The prior art is difficult to effectively regulate the inflammatory response, resulting in tissue inflammation damage and wound healing difficulties.
By using mesenchymal stem cells, especially human allogeneic adipose mesenchymal stem cells, the proliferation of lymphocytes, Th1 cells, and Th17 cells is inhibited, the secretion of the inflammatory factor TNF-α is inhibited, and the proliferation of Treg lymphocytes and the expression of IDO are promoted, thereby regulating immunity. reaction and reduce inflammatory response.
Through paracrine mechanisms and interactions with immune cells, mesenchymal stem cells successfully regulate the balance of immune responses, downregulate local inflammatory responses, reduce tissue inflammatory damage, and promote wound healing.
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to an application of mesenchymal stem cells in reconstructing immune barriers at inflammatory sites. Background Art
[0002] Mesenchymal stem cells (MSCs) are a type of adult stem cell with multidirectional differentiation potential, which can differentiate into a variety of tissue cells such as bone, cartilage, fat, muscle, etc. Mesenchymal stem cells mainly come from bone marrow, but can also come from adult tissues such as umbilical cord, fat, liver, lung, muscle and kidney.
[0003] The International Society for Cellular Therapy defines mesenchymal stem cells as: 1. They grow adherently and have a fibroblast-like morphology. 2. They express surface antigens of stromal cells, but not hematopoietic cell surface antigens. 3. They have the potential to differentiate into osteoblasts, adipocytes, and chondrocytes. In addition to their strong self-renewal ability and multidirectional differentiation potential, mesenchymal stem cells have the ability to promote the regeneration and repair of damaged tissues. They also have a strong regulatory effect on the body's immune function, mainly by inhibiting immune responses by affecting the proliferation, differentiation, and secretion of immune factors of immune cells. Therefore, mesenchymal stem cells show strong anti-inflammatory ability.
[0004] Adipose-Derived Stem Cells (ADSC) are stem cells isolated from adipose tissue and have multidirectional differentiation potential.
[0005] Studies have shown that 2% of cells in adipose tissue are adipose stem cells, which is much higher than the proportion obtained from the bone marrow (0.002%). The proliferation rate in vitro is higher than that of bone marrow stem cells, and they do not express NK receptor ligands and will not cause immune rejection reactions. Therefore, ADSCs have shown application prospects that other stem cells cannot achieve. Summary of the invention
[0006] The present invention provides an application of mesenchymal stem cells to reconstruct immune barriers at inflammatory sites.
[0007] To achieve the above object, the present invention provides the following technical solutions:
[0008] An application of mesenchymal stem cells to reconstruct the immune barrier at the site of inflammation. The specific mechanism is that mesenchymal stem cells inhibit the proliferation of lymphocytes, Th1 cells, and Th17 cells, inhibit the secretion of inflammatory factor TNF-α by activated immune cells, promote the proliferation of Treg lymphocytes and the expression of IDO, and through this immune regulation, reduce the inflammatory response, thereby healing the wound.
[0009] The mesenchymal stem cells are human allogeneic adipose-derived mesenchymal stem cells.
[0010] Compared with the prior art, the beneficial effects of the present invention are: mesenchymal stem cells can mediate and regulate the balance of immune response through paracrine mechanism and the interaction between mesenchymal stem cells and immune cells, and finally promote the downregulation of local inflammatory response and reduce tissue inflammatory damage. The regulation of inflammatory immune response by mesenchymal stem cells mainly includes the regulation of innate immunity and acquired immune response. DETAILED DESCRIPTION
[0011] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0012] Example
[0013] An application of mesenchymal stem cells to reconstruct the immune barrier at the site of inflammation. The specific mechanism is that mesenchymal stem cells inhibit the proliferation of lymphocytes, Th1 cells, and Th17 cells, inhibit the secretion of inflammatory factor TNF-α by activated immune cells, promote the proliferation of Treg lymphocytes and the expression of IDO, and through this immune regulation, reduce the inflammatory response, thereby healing the wound.
[0014] The mesenchymal stem cells are human allogeneic adipose-derived mesenchymal stem cells.
[0015] In the specific implementation, the monoclonal antibody biological product DK-001 derived from mesenchymal stem cells was used. DK-001 showed good therapeutic effects in the rat Crohn's disease model, and the pharmacodynamic effects between high, medium and low doses showed dose correlation.
[0016] Mesenchymal stem cells can increase the phagocytic ability of macrophages through interaction. Mesenchymal stem cells interact with macrophages to upregulate the expression of molecules related to phagocytic function in macrophages, such as scavenger receptors, etc., so that macrophages can enhance their phagocytic function against pathogens and reduce the number of invading pathogens. On the one hand, it reduces the direct damage of pathogens to the lesion site, and on the other hand, it reduces the stimulation of pathogen components on immune cells, thereby reducing local inflammatory damage and systemic inflammatory response.
Claims
1. An application of mesenchymal stem cells to reconstruct immune barriers at inflammatory sites, characterized in that The specific mechanism is that mesenchymal stem cells inhibit the proliferation of lymphocytes, Th1 cells, and Th17 cells, inhibit the secretion of inflammatory factor TNF-α by activated immune cells, promote the proliferation of Treg lymphocytes and the expression of IDO, and through this immune regulation, reduce the inflammatory response, thereby healing the wound.
2. The use of mesenchymal stem cells for reconstructing immune barriers at inflammatory sites according to claim 1, characterized in that The mesenchymal stem cells are human allogeneic adipose-derived mesenchymal stem cells.